Invitrogen™ IL-33R (ST2) Monoclonal Antibody (RMST2-33), PE, eBioscience™, Invitrogen™

Description

Description: The RMST2-33 monoclonal antibody reacts with mouse ST2, also known as IL-33R or interleukin 1 receptor-like 1. ST2 is a member of the IL-1 receptor family. In the membrane-bound form, it consists of three extracellular immunoglobulin domains and an intracellular toll-interleukin-1 receptor domain. ST2 forms a dimer with IL-1R accessory protein in a ligand-dependent manner. IL-33/ST2 interaction induces the production of TH2 cytokines. ST2 also has a soluble isoform lacking transmembrane and intracellular toll-interleukin-1 receptor domains. It is believed that the soluble form functions as a decoy receptor that can block membrane bound IL-33/ST2 interaction. ST2 is expressed by TH2 lymphocytes, mast cells, eosinophils, basophils, innate lymphocytes, smooth muscle cells, and endothelial cells and is involved in host defense, allergy, and inflammation. IL-33/ST2 interaction has also been shown to be atheroprotective. RMST2-33 has been reported to bind and activate ST2 in in vitro assays. Applications Reported: This RMST2-33 antibody has been reported for use in flow cytometric analysis. Applications Tested: This RMST2-33 antibody has been tested by flow cytometric analysis of mouse bone marrow-derived mast cells. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

IL-33R, also known as ST2, is a receptor for IL-33. It is a member of the IL-1 receptor family of innate receptors. Its extracellular domain consists of 3 Ig-like domains that directly interact with its co-receptor IL-1RAcP, and the ligand alarmin, IL-33. IL-33 ligation results in the association of IL-33R complex with its adaptor proteins MyD88, IRAK1, IRAK4 and TRAF6, and activation of the NF-kB, and MAPK pathways. This, in turn, instigates the release of chemokines and cytokines such as IL-5, IL-6, IL-8, and IL-13. Two most common isoforms of IL-33R that result from alternative splicing are ST2L - the membrane bound form, and ST2S - the soluble form. The membrane bound form can be released from the cell surface by proteolytic cleavage. The soluble forms have been suggested to act as decoys dampening the IL-33 signaling. IL-33R is primarily expressed by mast cells, basophils, and eosinophils. In mouse, IL-33R expression has been shown on ILC2 and Th2 cells. IL-33R signaling has been implicated in the number of immune conditions, including allergies, arthritis, atherosclerosis and sepsis.